MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Atidarymo kaina

14.68 1.8

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.24

Max

14.8

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -12M
Darbuotojai	37
EBITDA	-2.1M -12M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+121.76% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-206M 1.1B
Ankstesnė atidarymo kaina	12.88
Ankstesnė uždarymo kaina	14.68

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-02 17:11; UTC

Pagrindinės rinkos jėgos

Svarbiausios naujienos

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2026-04-02 17:10; UTC

Svarbiausios naujienos

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

2026-04-03 00:00; UTC

Svarbiausios naujienos

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2026-04-02 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2026-04-02 21:01; UTC

Svarbiausios naujienos

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2026-04-02 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks and Boyu Capital Finalize China JV

2026-04-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-02 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-02 20:41; UTC

Uždarbis

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026-04-02 20:32; UTC

Rinkos pokalbiai

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2026-04-02 20:30; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 20:09; UTC

Rinkos pokalbiai

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2026-04-02 20:01; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 19:46; UTC

Rinkos pokalbiai

Is Oil the New GameStop? -- Market Talk

2026-04-02 19:35; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2026-04-02 19:29; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 19:24; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2026-04-02 19:20; UTC

Rinkos pokalbiai

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2026-04-02 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2026-04-02 19:00; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: Agreement Reached With American Train Dispatchers Association

2026-04-02 18:24; UTC

Įsigijimai, susijungimai, perėmimai

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2026-04-02 17:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2026-04-02 17:32; UTC

Svarbiausios naujienos

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2026-04-02 17:26; UTC

Uždarbis

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026-04-02 17:17; UTC

Rinkos pokalbiai

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2026-04-02 17:09; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

121.76% į viršų

12 mėnesių prognozė

Vidutinis 32 USD 121.76%

Aukščiausias 42 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.